Category Archives: Corporate Responsibility

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Also posted in Biotech, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Confessions of a Compliance Director

In anticipation of CBI’s (a PharmExec sibling company) 11th Annual Pharma Compliance Congress happening later this month, PharmExec spoke with a compliance director at a mid-sized pharma ($5 billion in annual sales) about life under a CIA, and the potential trigger issues for 2014. In an effort to promote candor and avoid overly circumspect responses, […]
Also posted in compliance, E-Media, Emerging Markets, FDA, healthcare, Legal, Marketing, Medical Education, pricing, Regulatory, Sales, social media, Strategy | Tagged , , , , , , , , , , , , , , | Leave a comment

Typhoon Trauma: The Pharma Score on Disaster Relief

Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month.  Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created […]
Also posted in Emerging Markets, Global | Tagged , , , , , , , | Leave a comment

The Vanishing Rx Patient Assistance Programs?

by Tom Norton In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters. In response to the Clinton’s charges that the industry was “price gouging,” my firm was proposing that we provide free prescription products to any patients who could not […]
Also posted in Guest Blog, healthcare, Legal, Market Access, Patient Communication | Tagged , , , , , , , | Leave a comment

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Also posted in Deals, Emerging Markets, Global, IP, Market Access, pricing | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta